Breast Cancer

Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.

Dr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity

Three prominent breast cancer clinicians and researchers share their opinions on adjuvant anthracyclines, fluoropyrimidines, and taxane agents for women with early breast cancer.

In a six-week span, José Baselga, MD, PhD, notched a stunning series of milestones in breast cancer research that could potentially change practice in different subtypes of the disease.

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

J. Michael Dixon, MBChB, MD, and Patrick I. Borgen, MD, discuss the pros and cons of long-term clinical follow-up care of patients with breast cancer.

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

Dr. J. Michael Dixon, from Western General Hospital, Scotland, Advises Against Mastectomies

A discussion with Pat Whitworth, Jr, MD, on how breast cancer treatment has evolved from a 'kitchen sink' approach with chemotherapy to a new paradigm that targets chemosensitivity.

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, was one of four co-chairs of the 2012 Miami Breast Cancer Conference.

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

Monitoring bone health and ensuring adequate calcium and vitamin D intake in postmenopausal women who are taking exemestane for the primary prevention of breast cancer is essential.

Dr. Maxine Jochelson, from Memorial Sloan-Kettering Cancer Center, Discusses Complementary Breast Cancer Screening Techniques

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Dr. Pat Whitworth, from the Vanderbilt University Medical Center, Discusses Chemotherapy for Breast Cancer

Quoting statistics seemed to be a refuge to me. The objectivity of the numbers provided a hiding place and a shelter, and they helped me maintain the emotional distance that my profession demanded.

Dr. Eleftherios Mamounas, from Aultman Hospital Cancer Center, on Predicting the Risk of DCIS Recurrence

Dr. Neil Spector, from Duke Cancer Institute, Discusses the Systemic Nature of Cancer

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

A new test specifically designed for breast cancer patients with DCIS appears to be a better indicator of recurrence than other assays for more invasive forms of the disease.

Patients who undergo chemotherapy for breast cancer may develop fatigue that remains problematic long after they complete treatment.

Adjuvant chemotherapy improves disease-free and overall survival in many--but not all--patients with breast cancer.